Advertisement

CNS Drugs

pp 1–17 | Cite as

Phytomedicines in the Treatment of Migraine

  • Thilinie Rajapakse
  • William Jeptha Davenport
Leading Article

Abstract

Migraine is a disabling neurovascular disorder with few targeted, tolerable and effective treatments. Phytomedicines, or plant-based medicinal formulations, hold great promise in the identification of novel therapeutic targets in migraine. Many patients also turn toward herbal and plant-based therapies for the treatment of their migraines as clinical and preclinical evidence of efficacy increases. Patients seek effective and tolerable treatments instead of or in addition to current conventional pharmacologic therapies. We review some phytomedicines potentially useful for migraine treatment—feverfew (Tanacetum parthenium), butterbur (Petasites hybridus), marijuana (Cannabis spp.), Saint John’s Wort (Hypericum perforatum) and the Damask rose (Rosa × damascena)—with respect to their mechanisms of action and evidence for treatment of migraine. The evidence for feverfew is mixed; butterbur is effective with potential risks of hepatotoxicity related to preparation; marijuana has not been shown to be effective in migraine treatment, and data are scant; Saint John’s Wort shows relevant physiological activity but is a hepatic enzyme inducer and lacks clinical studies for this purpose; the Damask rose when used in topical preparations did not show efficacy in one clinical trial. Other plant preparations have been considered for migraine treatment but most without blinded randomized, placebo-controlled trial evidence.

Notes

Compliance with Ethical Standards

Funding

No sources of funding were used to prepare this manuscript.

Conflict of interest

Thilinie Rajapakse and William Jeptha Davenport have no conflicts of interest that are directly relevant to the content of this study.

References

  1. 1.
    Noseda R, Burstein R. Migraine pathophysiology: anatomy of the trigeminovascular pathway and associated neurological symptoms, cortical spreading depression, sensitization, and modulation of pain. Pain. 2013;154(Suppl 1):S44–53.PubMedCrossRefGoogle Scholar
  2. 2.
    Burstein R, Noseda R, Borsook D. Migraine: multiple processes, complex pathophysiology. J Neurosci Off J Soc Neurosci. 2015;35:6619–29.CrossRefGoogle Scholar
  3. 3.
    GBD 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol. 2017;16:877–97.CrossRefGoogle Scholar
  4. 4.
    Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97:553–622.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Rajapakse T, Pringsheim T. Nutraceuticals in migraine: a summary of existing guidelines for use. Headache. 2016;56:808–16.PubMedCrossRefGoogle Scholar
  6. 6.
    Headache Classification Committee of the International Headache Society. The international classification of headache disorders, 3rd edition. Cephalalgia Int J Headache. 2018;38:1–211.Google Scholar
  7. 7.
    Olesen J, Burstein R, Ashina M, Tfelt-Hansen P. Origin of pain in migraine: evidence for peripheral sensitisation. Lancet Neurol. 2009;8:679–90.PubMedCrossRefGoogle Scholar
  8. 8.
    Levy D, Strassman AM. Mechanical response properties of A and C primary afferent neurons innervating the rat intracranial dura. J Neurophysiol. 2002;88:3021–31.PubMedCrossRefGoogle Scholar
  9. 9.
    Collado-Vázquez S, Carrillo JM. Cranial trepanation in the Egyptian. Neurol Barc Spain. 2014;29:433–40.Google Scholar
  10. 10.
    Zargaran A, Borhani-Haghighi A, Faridi P, Daneshamouz S, Mohagheghzadeh A. A review on the management of migraine in the Avicenna’s Canon of Medicine. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol. 2016;37:471–8.Google Scholar
  11. 11.
    Abokrysha N. Ibn Sina (Avicenna) on pathogenesis of migraine compared with the recent theories. Headache. 2009;49:923–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Heptinstall S, Awang DV, Dawson BA, Kindack D, Knight DW, May J. Parthenolide content and bioactivity of Feverfew (Tanacetum parthenium (L.) Schultz-Bip.). Estimation of commercial and authenticated feverfew products. J Pharm Pharmacol. 1992;44:391–5.PubMedCrossRefGoogle Scholar
  13. 13.
    Awang DVC. Prescribing therapeutic Feverfew (Tanacetum parthenium (L.) Schultz Bip., syn. Chrysanthemum parthenium (L.) Bernh.). Integr Med. 1998;1:11–3.CrossRefGoogle Scholar
  14. 14.
    Collier HO, Butt NM, McDonald-Gibson WJ, Saeed SA. Extract of feverfew inhibits prostaglandin biosynthesis. Lancet Lond Engl. 1980;2:922–3.CrossRefGoogle Scholar
  15. 15.
    Makheja AN, Bailey JM. A platelet phospholipase inhibitor from the medicinal herb feverfew (Tanacetum parthenium). Prostaglandins Leukot Med. 1982;8:653–60.PubMedGoogle Scholar
  16. 16.
    Heptinstall S, White A, Williamson L, Mitchell JR. Extracts of feverfew inhibit granule secretion in blood platelets and polymorphonuclear leucocytes. Lancet Lond Engl. 1985;1:1071–4.CrossRefGoogle Scholar
  17. 17.
    Marles RJ, Kaminski J, Arnason JT, Pazos-Sanou L, Heptinstall S, Fischer NH, et al. A bioassay for inhibition of serotonin release from bovine platelets. J Nat Prod. 1992;55:1044–56.PubMedCrossRefGoogle Scholar
  18. 18.
    Brinker F. Herb contraindications and drug interactions. 3rd ed. Sandy: Eclectic Medical Publications; 2001.Google Scholar
  19. 19.
    McGuffin M. American Herbal Products Association’s botanical safety handbook. Boca Raton: CRC Press; 1997.Google Scholar
  20. 20.
    Pittler MH, Ernst E. Feverfew for preventing migraine. Cochrane Database Syst Rev. 2004;CD002286.Google Scholar
  21. 21.
    Wider B, Pittler MH, Ernst E. Feverfew for preventing migraine. Cochrane Database Syst Rev. 2015;4:CD002286.Google Scholar
  22. 22.
    Diener HC, Pfaffenrath V, Schnitker J, Friede M, Henneicke-von Zepelin H-H. Efficacy and safety of 6.25 mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention—a randomized, double-blind, multicentre, placebo-controlled study. Cephalalgia Int J Headache. 2005;25:1031–41.CrossRefGoogle Scholar
  23. 23.
    De Weerdt CJ, Bootsma HP, Hendriks H. Herbal medicines in migraine prevention randomized double-blind placebo-controlled crossover trial of a feverfew preparation. Phytomed Int J Phytother Phytopharm. 1996;3:225–30.Google Scholar
  24. 24.
    Pfaffenrath V, Diener HC, Fischer M, Friede M, Henneicke-von Zepelin HH, Investigators. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis—a double-blind, multicentre, randomized placebo-controlled dose-response study. Cephalalgia Int J Headache. 2002;22:523–32.CrossRefGoogle Scholar
  25. 25.
    National Center for Complementary and Integrative Health. Butterbur [Internet]. 2017. https://nccih.nih.gov/health/butterbur. Accessed 2018 Aug 15.
  26. 26.
    Taylor FR. Nutraceuticals and headache: the biological basis. Headache. 2011;51:484–501.PubMedCrossRefGoogle Scholar
  27. 27.
    Prieto J. Update on the efficacy and safety of Petadolex®, a butterbur extract for migraine prophylaxis. Bot Targets Ther. 2014;2:1–9.Google Scholar
  28. 28.
    Brune K, Bickel D, Peskar BA. Gastro-protective effects by extracts of Petasites hybridus: the role of inhibition of peptido-leukotriene synthesis. Planta Med. 1993;59:494–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Benemei S, De Logu F, Li Puma S, Marone IM, Coppi E, Ugolini F, et al. The anti-migraine component of butterbur extracts, isopetasin, desensitizes peptidergic nociceptors by acting on TRPA1 cation channel. Br J Pharmacol. 2017;174:2897–911.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Benemei S, Fusi C, Trevisan G, Geppetti P. The TRPA1 channel in migraine mechanism and treatment. Br J Pharmacol. 2014;171:2552–67.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Sheykhzade M, Smajilovic S, Issa A, Haunso S, Christensen SB, Tfelt-Hansen J. S-petasin and butterbur lactones dilate vessels through blockage of voltage gated calcium channels and block DNA synthesis. Eur J Pharmacol. 2008;593:79–86.PubMedCrossRefGoogle Scholar
  32. 32.
    Fiebich BL, Grozdeva M, Hess S, Hüll M, Danesch U, Bodensieck A, et al. Petasites hybridus extracts in vitro inhibit COX-2 and PGE2 release by direct interaction with the enzyme and by preventing p42/44 MAP kinase activation in rat primary microglial cells. Planta Med. 2005;71:12–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Levy D, Burstein R, Kainz V, Jakubowski M, Strassman AM. Mast cell degranulation activates a pain pathway underlying migraine headache. Pain. 2007;130:166–76.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Shimoda H, Tanaka J, Yamada E, Morikawa T, Kasajima N, Yoshikawa M. Anti type I allergic property of Japanese butterbur extract and its mast cell degranulation inhibitory ingredients. J Agric Food Chem. 2006;54:2915–20.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Pringsheim T, Davenport WJ, Mackie G, Worthington I, Aubé M, Christie SN, et al. Canadian Headache Society guideline for migraine prophylaxis. Can J Neurol Sci J Can Sci Neurol. 2012;39:S1–59.CrossRefGoogle Scholar
  36. 36.
    Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E, et al. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1346–53.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Lipton RB, Göbel H, Einhäupl KM, Wilks K, Mauskop A. Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. Neurology. 2004;63:2240–4.PubMedCrossRefGoogle Scholar
  38. 38.
    Diener HC, Rahlfs VW, Danesch U. The first placebo-controlled trial of a special butterbur root extract for the prevention of migraine: reanalysis of efficacy criteria. Eur Neurol. 2004;51:89–97.PubMedCrossRefGoogle Scholar
  39. 39.
    Mauskop A. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2013;80:868.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, et al. EFNS guideline on the drug treatment of migraine–revised report of an EFNS task force. Eur J Neurol Off J Eur Fed Neurol Soc. 2009;16:968–81.Google Scholar
  41. 41.
  42. 42.
    Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163:1344–64.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Baron EP. Comprehensive review of medicinal Marijuana, Cannabinoids, and therapeutic implications in medicine and headache: what a long strange trip it’s been …. Headache. 2015;55:885–916.PubMedCrossRefGoogle Scholar
  44. 44.
    Battista N, Di Tommaso M, Bari M, Maccarrone M. The endocannabinoid system: an overview. Front Behav Neurosci. 2012;6:9.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Iversen L. Cannabis and the brain. Brain J Neurol. 2003;126:1252–70.CrossRefGoogle Scholar
  46. 46.
    Palkovits M, Harvey-White J, Liu J, Kovacs ZS, Bobest M, Lovas G, et al. Regional distribution and effects of postmortal delay on endocannabinoid content of the human brain. Neuroscience. 2008;152:1032–9.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Katona I, Freund TF. Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med. 2008;14:923–30.PubMedCrossRefGoogle Scholar
  48. 48.
    Fan P. Cannabinoid agonists inhibit the activation of 5-HT3 receptors in rat nodose ganglion neurons. J Neurophysiol. 1995;73:907–10.PubMedCrossRefGoogle Scholar
  49. 49.
    Elsohly MA, Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci. 2005;78:539–48.PubMedCrossRefGoogle Scholar
  50. 50.
    Hillig KW, Mahlberg PG. A chemotaxonomic analysis of cannabinoid variation in Cannabis (Cannabaceae). Am J Bot. 2004;91:966–75.PubMedCrossRefGoogle Scholar
  51. 51.
    Ashton CH. Pharmacology and effects of cannabis: a brief review. Br J Psychiatry J Ment Sci. 2001;178:101–6.CrossRefGoogle Scholar
  52. 52.
    Williamson EM, Evans FJ. Cannabinoids in clinical practice. Drugs. 2000;60:1303–14.PubMedCrossRefGoogle Scholar
  53. 53.
    Hampson AJ, Grimaldi M, Lolic M, Wink D, Rosenthal R, Axelrod J. Neuroprotective antioxidants from marijuana. Ann N Y Acad Sci. 2000;899:274–82.PubMedCrossRefGoogle Scholar
  54. 54.
    Lichtman AH, Cook SA, Martin BR. Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement. J Pharmacol Exp Ther. 1996;276:585–93.PubMedGoogle Scholar
  55. 55.
    Bushlin I, Rozenfeld R, Devi LA. Cannabinoid–opioid interactions during neuropathic pain and analgesia. Curr Opin Pharmacol. 2010;10:80–6.PubMedCrossRefGoogle Scholar
  56. 56.
    Akerman S, Holland PR, Goadsby PJ. Cannabinoid (CB1) receptor activation inhibits trigeminovascular neurons. J Pharmacol Exp Ther. 2007;320:64–71.PubMedCrossRefGoogle Scholar
  57. 57.
    McGeeney BE. Cannabinoids and hallucinogens for headache. Headache. 2013;53:447–58.PubMedCrossRefGoogle Scholar
  58. 58.
    Lochte BC, Beletsky A, Samuel NK, Grant I. The use of cannabis for headache disorders. Cannabis Cannabinoid Res. 2017;2:61–71.PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Russo E. Hemp for headache: an in-depth historical and scientific review of cannabis in migraine treatment. J Cannabis Ther. 2001;1:21–92.CrossRefGoogle Scholar
  60. 60.
    Noyes R, Baram DA. Cannabis analgesia. Compr Psychiatry. 1974;15:531–5.PubMedCrossRefGoogle Scholar
  61. 61.
    El-Mallakh RS. Marijuana and migraine. Headache. 1987;27:442–3.PubMedCrossRefGoogle Scholar
  62. 62.
    El-Mallakh RS. Migraine headaches and drug abuse. South Med J. 1989;82:805.PubMedCrossRefGoogle Scholar
  63. 63.
    Milstein SL, MacCannell K, Karr G, Clark S. Marijuana-produced changes in pain tolerance. Experienced and non-experienced subjects. Int Pharmacopsychiatry. 1975;10:177–82.PubMedCrossRefGoogle Scholar
  64. 64.
    Noyes R, Brunk SF, Avery DA, Canter AC. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther. 1975;18:84–9.PubMedCrossRefGoogle Scholar
  65. 65.
    Aggarwal SK. Cannabinergic pain medicine: a concise clinical primer and survey of randomized-controlled trial results. Clin J Pain. 2013;29:162–71.PubMedCrossRefGoogle Scholar
  66. 66.
    Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet Lond Engl. 2009;374:1383–91.CrossRefGoogle Scholar
  67. 67.
    Sachs J, McGlade E, Yurgelun-Todd D. Safety and toxicology of cannabinoids. Neurother J Am Soc Exp Neurother. 2015;12:735–46.CrossRefGoogle Scholar
  68. 68.
    Reece AS. Chronic toxicology of cannabis. Clin Toxicol Phila Pa. 2009;47:517–24.CrossRefGoogle Scholar
  69. 69.
    Vuralli D, Ayata C, Bolay H. Cognitive dysfunction and migraine. J Headache Pain. 2018;19:109.PubMedCrossRefGoogle Scholar
  70. 70.
    Crane NA, Schuster RM, Fusar-Poli P, Gonzalez R. Effects of cannabis on neurocognitive functioning: recent advances, neurodevelopmental influences, and sex differences. Neuropsychol Rev. 2013;23:117–37.PubMedCrossRefGoogle Scholar
  71. 71.
    Schweinsburg AD, Brown SA, Tapert SF. The influence of marijuana use on neurocognitive functioning in adolescents. Curr Drug Abuse Rev. 2008;1:99–111.PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    Repp K, Raich A. Marijuana and health: a comprehensive review of 20 years of research [Internet]. 2014. https://www.co/washington.or.us/HHS/News/upload/Marijuana-review.pdf. Accessed 18 Nov 2018.
  73. 73.
    Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RSE, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci USA. 2012;109:E2657–64.PubMedCrossRefGoogle Scholar
  74. 74.
    Kasper S, Caraci F, Forti B, Drago F, Aguglia E. Efficacy and tolerability of hypericum extract for the treatment of mild to moderate depression. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2010;20:747–65.CrossRefGoogle Scholar
  75. 75.
    Galeotti N, Vivoli E, Bilia AR, Bergonzi MC, Bartolini A, Ghelardini C. A prolonged protein kinase C-mediated, opioid-related antinociceptive effect of st John’s Wort in mice. J Pain Off J Am Pain Soc. 2010;11:149–59.CrossRefGoogle Scholar
  76. 76.
    Galeotti N, Vivoli E, Bilia AR, Vincieri FF, Ghelardini C. St. John’s Wort reduces neuropathic pain through a hypericin-mediated inhibition of the protein kinase Cgamma and epsilon activity. Biochem Pharmacol. 2010;79:1327–36.PubMedCrossRefGoogle Scholar
  77. 77.
    Galeotti N, Ghelardini C. St. John’s wort reversal of meningeal nociception: a natural therapeutic perspective for migraine pain. Phytomedicine Int J Phytother Phytopharm. 2013;20:930–8.CrossRefGoogle Scholar
  78. 78.
    Rahimi R, Nikfar S, Abdollahi M. Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:118–27.PubMedCrossRefGoogle Scholar
  79. 79.
    Whitten DL, Myers SP, Hawrelak JA, Wohlmuth H. The effect of St John’s wort extracts on CYP3A: a systematic review of prospective clinical trials. Br J Clin Pharmacol. 2006;62:512–26.PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Niazi M, Hashempur MH, Taghizadeh M, Heydari M, Shariat A. Efficacy of topical Rose (Rosa damascena Mill) oil for migraine headache: a randomized double-blinded placebo-controlled cross-over trial. Complement Ther Med. 2017;34:35–41.PubMedCrossRefGoogle Scholar
  81. 81.
    Serna-Jiménez CE, del Rio-Sancho S, Calatayud-Pascual MA, Balaguer-Fernández C, Femenía-Font A, López-Castellano A, et al. Development of antimigraine transdermal delivery systems of pizotifen malate. Int J Pharm. 2015;492:223–32.PubMedCrossRefGoogle Scholar
  82. 82.
    Delavar Kasmaei H, Ghorbanifar Z, Zayeri F, Minaei B, Kamali SH, Rezaeizadeh H, et al. Effects of Coriandrum sativum syrup on migraine: a randomized, triple-blind, placebo-controlled trial. Iran Red Crescent Med J. 2016;18:e20759.PubMedPubMedCentralCrossRefGoogle Scholar
  83. 83.
    Kamali M, Seifadini R, Kamali H, Mehrabani M, Jahani Y, Tajadini H. Efficacy of combination of Viola odorata, Rosa damascena and Coriandrum sativum in prevention of migraine attacks: a randomized, double blind, placebo-controlled clinical trial. Electron Physician. 2018;10:6430–8.PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    Humphrey RW, Brockway-Lunardi LM, Bonk DT, Dohoney KM, Doroshow JH, Meech SJ, et al. Opportunities and challenges in the development of experimental drug combinations for cancer. J Natl Cancer Inst. 2011;103:1222–6.PubMedCrossRefGoogle Scholar
  85. 85.
    Nash KM, Shah ZA. Current perspectives on the beneficial role of Ginkgo biloba in neurological and cerebrovascular disorders. Integr Med Insights. 2015;10:1–9.PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    Allais G, D’Andrea G, Maggio M, Benedetto C. The efficacy of ginkgolide B in the acute treatment of migraine aura: an open preliminary trial. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol. 2013;34(Suppl 1):S161–3.Google Scholar
  87. 87.
    Usai S, Grazzi L, Andrasik F, Bussone G. An innovative approach for migraine prevention in young age: a preliminary study. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol. 2010;31(Suppl 1):S181–3.Google Scholar
  88. 88.
    Usai S, Grazzi L, Bussone G. Gingkolide B as migraine preventive treatment in young age: results at 1-year follow-up. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol. 2011;32(Suppl 1):S197–9.Google Scholar
  89. 89.
    Esposito M, Carotenuto M. Ginkgolide B complex efficacy for brief prophylaxis of migraine in school-aged children: an open-label study. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol. 2011;32:79–81.Google Scholar
  90. 90.
    D’Andrea G, Bussone G, Allais G, Aguggia M, D’Onofrio F, Maggio M, et al. Efficacy of Ginkgolide B in the prophylaxis of migraine with aura. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol. 2009;30(Suppl 1):S121–4.Google Scholar
  91. 91.
    Kayama Y, Shibata M, Takizawa T, Ibata K, Shimizu T, Ebine T, et al. Functional interactions between transient receptor potential M8 and transient receptor potential V1 in the trigeminal system: relevance to migraine pathophysiology. Cephalalgia Int J Headache. 2018;38:833–45.CrossRefGoogle Scholar
  92. 92.
    Borhani Haghighi A, Motazedian S, Rezaii R, Mohammadi F, Salarian L, Pourmokhtari M, et al. Cutaneous application of menthol 10% solution as an abortive treatment of migraine without aura: a randomised, double-blind, placebo-controlled, crossed-over study. Int J Clin Pract. 2010;64:451–6.PubMedCrossRefGoogle Scholar
  93. 93.
    Zargaran A, Borhani-Haghighi A, Faridi P, Daneshamouz S, Kordafshari G, Mohagheghzadeh A. Potential effect and mechanism of action of topical chamomile (Matricaria chamomilla L.) oil on migraine headache: a medical hypothesis. Med Hypotheses. 2014;83:566–9.PubMedCrossRefGoogle Scholar
  94. 94.
    Zargaran A, Borhani-Haghighi A, Salehi-Marzijarani M, Faridi P, Daneshamouz S, Azadi A, et al. Evaluation of the effect of topical chamomile (Matricaria chamomilla L.) oleogel as pain relief in migraine without aura: a randomized, double-blind, placebo-controlled, crossover study. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol. 2018;39:1345–53.Google Scholar
  95. 95.
    Cavin C, Delannoy M, Malnoe A, Debefve E, Touché A, Courtois D, et al. Inhibition of the expression and activity of cyclooxygenase-2 by chicory extract. Biochem Biophys Res Commun. 2005;327:742–9.PubMedCrossRefGoogle Scholar
  96. 96.
    Bhaskaran N, Shukla S, Srivastava JK, Gupta S. Chamomile: an anti-inflammatory agent inhibits inducible nitric oxide synthase expression by blocking RelA/p65 activity. Int J Mol Med. 2010;26:935–40.PubMedPubMedCentralGoogle Scholar
  97. 97.
    Singh O, Khanam Z, Misra N, Srivastava MK. Chamomile (Matricaria chamomilla L.): an overview. Pharmacogn Rev. 2011;5:82–95.PubMedPubMedCentralCrossRefGoogle Scholar
  98. 98.
    Georgiadou G, Tarantilis PA, Pitsikas N. Effects of the active constituents of Crocus sativus L., crocins, in an animal model of obsessive-compulsive disorder. Neurosci Lett. 2012;528:27–30.PubMedCrossRefGoogle Scholar
  99. 99.
    Hajhashemi V, Ghannadi A, Hajiloo M. Analgesic and anti-inflammatory effects of Rosa damascena hydroalcoholic extract and its essential oil in animal models. Iran J Pharm Res IJPR. 2010;9:163–8.PubMedGoogle Scholar
  100. 100.
    De Marino S, Borbone N, Zollo F, Ianaro A, Di Meglio P, Iorizzi M. New sesquiterpene lactones from Laurus nobilis leaves as inhibitors of nitric oxide production. Planta Med. 2005;71:706–10.PubMedCrossRefGoogle Scholar
  101. 101.
    Vision. Feverfew [Internet] Open access image. [Internet]. 2005. https://commons.wikimedia.org/wiki/File:feverfew.jpg. Accessed 18 Nov 2018.
  102. 102.
  103. 103.
    Leimuranta P, Khiroug L, Giniatullin R. Emerging role of (Endo) cannabinoids in migraine. Front Pharmacol. 2018;9:420.PubMedPubMedCentralCrossRefGoogle Scholar
  104. 104.
    Tognetto M, Amadesi S, Harrison S, Creminon C, Trevisani M, Carreras M, et al. Anandamide excites central terminals of dorsal root ganglion neurons via vanilloid receptor-1 activation. J Neurosci Off J Soc Neurosci. 2001;21:1104–9.CrossRefGoogle Scholar
  105. 105.
    Akerman S, Kaube H, Goadsby PJ. Anandamide acts as a vasodilator of dural blood vessels in vivo by activating TRPV1 receptors. Br J Pharmacol. 2004;142:1354–60.PubMedPubMedCentralCrossRefGoogle Scholar
  106. 106.
    Russo EB. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro Endocrinol Lett. 2008;29:192–200.PubMedGoogle Scholar
  107. 107.
    Juhasz G, Lazary J, Chase D, Pegg E, Downey D, Toth ZG, et al. Variations in the cannabinoid receptor 1 gene predispose to migraine. Neurosci Lett. 2009;461:116–20.PubMedCrossRefGoogle Scholar
  108. 108.
    Nyholt DR, Morley KI, Ferreira MAR, Medland SE, Boomsma DI, Heath AC, et al. Genomewide significant linkage to migrainous headache on chromosome 5q21. Am J Hum Genet. 2005;77:500–12.PubMedPubMedCentralCrossRefGoogle Scholar
  109. 109.
    Akerman S, Holland PR, Lasalandra MP, Goadsby PJ. Endocannabinoids in the brainstem modulate dural trigeminovascular nociceptive traffic via CB1 and “triptan” receptors: implications in migraine. J Neurosci Off J Soc Neurosci. 2013;33:14869–77.CrossRefGoogle Scholar
  110. 110.
    Jeong H-J, Chenu D, Johnson EE, Connor M, Vaughan CW. Sumatriptan inhibits synaptic transmission in the rat midbrain periaqueductal grey. Mol Pain. 2008;4:54.PubMedPubMedCentralCrossRefGoogle Scholar
  111. 111.
    Vaughan CW, Connor M, Bagley EE, Christie MJ. Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons in vitro. Mol Pharmacol. 2000;57:288–95.PubMedGoogle Scholar
  112. 112.
    Kazemi H, Rahgozar M, Speckmann E-J, Gorji A. Effect of cannabinoid receptor activation on spreading depression. Iran J Basic Med Sci. 2012;15:926–36.PubMedPubMedCentralGoogle Scholar
  113. 113.
    Heptinstall S, Groenewegen WA, Spangenberg P, Loesche W. Extracts of feverfew may inhibit platelet behaviour via neutralization of sulphydryl groups. J Pharm Pharmacol. 1987;39:459–65.PubMedCrossRefGoogle Scholar
  114. 114.
    Hayes NA, Foreman JC. The activity of compounds extracted from feverfew on histamine release from rat mast cells. J Pharm Pharmacol. 1987;39:466–70.PubMedCrossRefGoogle Scholar
  115. 115.
    Pugh WJ, Sambo K. Prostaglandin synthetase inhibitors in feverfew. J Pharm Pharmacol. 1988;40:743–5.PubMedCrossRefGoogle Scholar
  116. 116.
    Williams CA, Hoult JR, Harborne JB, Greenham J, Eagles J. A biologically active lipophilic flavonol from Tanacetum parthenium. Phytochemistry. 1995;38:267–70.PubMedCrossRefGoogle Scholar
  117. 117.
    Thomet OA, Wiesmann UN, Schapowal A, Bizer C, Simon HU. Role of petasin in the potential anti-inflammatory activity of a plant extract of Petasites hybridus. Biochem Pharmacol. 2001;61:1041–7.PubMedCrossRefGoogle Scholar
  118. 118.
    Wang GJ, Shum AY, Lin YL, Liao JF, Wu XC, Ren J, et al. Calcium channel blockade in vascular smooth muscle cells: major hypotensive mechanism of S-petasin, a hypotensive sesquiterpene from Petasites formosanus. J Pharmacol Exp Ther. 2001;297:240–6.PubMedGoogle Scholar
  119. 119.
    Volfe Z, Dvilansky A, Nathan I. Cannabinoids block release of serotonin from platelets induced by plasma from migraine patients. Int J Clin Pharmacol Res. 1985;5:243–6.PubMedGoogle Scholar
  120. 120.
    Formukong E, Garland LG, Evans AT, Evans FJ. Inhibition of A23187 induced release of CTB4 in mouse blood in vivo and human polymorphonuclear cells in vitro by analgesic cannabidiol. Phytother Res. 1991;5:258–61.CrossRefGoogle Scholar
  121. 121.
    Johnson ES, Kadam NP, Hylands DM, Hylands PJ. Efficacy of feverfew as prophylactic treatment of migraine. Br Med J Clin Res Ed. 1985;291:569–73.PubMedPubMedCentralCrossRefGoogle Scholar
  122. 122.
    Murphy JJ, Heptinstall S, Mitchell JR. Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet. 1988;2:189–92.PubMedCrossRefGoogle Scholar
  123. 123.
    Palevitch D, Earon G, Carasso R. Feverfew (Tanacetum parthenium) as a prophylactic treatment for migraine: a double-blind placebo-controlled study. Phytother Res. 1997;11:508–11.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Thilinie Rajapakse
    • 1
    • 5
  • William Jeptha Davenport
    • 2
    • 3
    • 4
  1. 1.Division of Neurology, Department of PediatricsFaculty of Medicine and Dentistry, University of AlbertaEdmontonCanada
  2. 2.Department of Clinical NeurosciencesCumming School of Medicine, University of CalgaryCalgaryCanada
  3. 3.Department of Medical GeneticsCumming School of Medicine, University of CalgaryCalgaryCanada
  4. 4.Hotchkiss Brain Institute, University of CalgaryCalgaryCanada
  5. 5.Women and Children’s Research InstituteEdmontonCanada

Personalised recommendations